without blocking the related enzyme COX-1.
Researchers thought this would avert gut problems, but some experts fear that inhibiting COX-2 alone can also increase the body's ability to produce heart-stopping blood clots.
Several years ago, studies began to emerge suggesting that people taking Vioxx had an increased risk of heart attack. In 2000, Merck started a study to assess the anticancer potential of Vioxx -it hoped the drug would prevent the formation of colon polyps, which typically overexpress COX-2. But it found that participants taking Vioxx for an average of 18 months experienced twice as many cardiovascular events as those on a placebo.
The company ended the trial prematurely and withdrew Vioxx from the market last year.
Plain speaking
Carol Ernst's case hinged as much on the amount Merck knew about Vioxx's risks before the withdrawal as on whether the drug was the direct cause of her husband's death. Jurors said they felt the drug company was hiding information about Vioxx, and voted accordingly.
It was not easy for lawyers to link Robert Ernst's death to the painkiller. Merck supporters point out that there are no studies associating Vioxx with fatal or non-fatal arrythmias, adding that Robert Ernst had been taking Vioxx for a far shorter time than the 18 months that was linked to heart attacks.
His autopsy uncovered no evidence of a blood clot. But the former local coroner testified at the trial that a blood clot could have dissipated before the examination.
Jurors had to feel convinced only that it was more likely than not that Vioxx was linked to Robert Ernst's death. And their decision did not have to be unanimous; in fact, two of the twelve jurors sided with Merck. Some observers believe that the outcome had more to do with sending a message to the pharmaceutical company than pinning down the cause of one particular death. Merck's stock fell by almost 8% after the verdict was announced.
Plaintiffs in other countries, including Britain, are now making plans to come to the United States, where legal conditions are more favourable for their claims.
The Ernst case was not considered the strongest among those pending, but the verdict should not give others carte blanche to launch into Merck, warns Howard Erichson of Seton Hall Law School in Newark, New Jersey. "You can't assume just because one plaintiff won that all plaintiffs will win. "
Merck is likely to make a series of legal appeals. 
